Trump signs executive order seeking to overhaul childhood vaccine schedule, splitting MMR vaccine
The order aims to split the MMR vaccine into separate shots and slim down the immunization schedule, drawing broad pushback from WHO, doctors, and the pharma in
BioPharma Dive · +14 outlets
WHO says Trump's latest vaccine policy order is misguided
World health leaders warn the executive order could subject children to more needles and greater disease risk.
STAT · +4 outlets
Patients die after treatment with Neurocrine's approved Prader-Willi drug Vykat
A series of patient deaths may be tied to the newly approved Prader-Willi syndrome drug, raising urgent safety concerns.
STAT · +14 outlets
Novo Nordisk's ziltivekimab misses Phase 3 primary endpoint
The experimental drug failed to meet its main goal in a late-stage trial, a setback for Novo Nordisk's pipeline.
drugdiscoverytrends.com · +8 outlets
Eli Lilly files six lawsuits targeting 'black market' sellers of experimental obesity drug retatrutide
Ahead of an approval filing, Lilly is suing US companies accused of illegally selling unapproved versions of its triple-G obesity medicine.
BioPharma Dive · +12 outlets
Definium Therapeutics says LSD therapy eases generalized anxiety disorder in late-stage trial
Results from a Phase 3 study show Definium's LSD-based treatment significantly helped patients with generalized anxiety disorder.
STAT · +8 outlets
Scientists create female clones of male mice using CRISPR to remove the Y chromosome
A Japanese team used CRISPR to turn male mouse embryos into females, a first in mammalian biology.
Biotechnology and health · +14 outlets
Epicrispr raises $90M Series C for epigenetic editing drug targeting rare muscle disease FSHD
The startup will use the oversubscribed round to advance a first-in-class epigenetic therapy toward pivotal studies in facioscapulohumeral muscular dystrophy.
BioPharma Dive · +5 outlets
Epicrispr bags $90M to advance epigenetic editing drug for rare muscle disease
The Series C will fund a first-in-class epigenetic therapy for facioscapulohumeral muscular dystrophy into pivotal studies.
BioPharma Dive · +4 outlets
In vivo CRISPR screen identifies gene edits that strengthen CAR-T therapy against solid tumors
Researchers used a CRISPR screen in living animals to find edits that could make CAR-T cells more effective against solid tumors.
Medical Xpress · +14 outlets
Vaderis nets $152M Series B to test AKT-targeting drug for rare bleeding disorder HHT
The startup is one of several focusing on hereditary hemorrhagic telangiectasia with a more precise AKT blocker, now heading to Phase 3.
BioPharma Dive · +1 outlets
A CRISPR-armed phage cures post-transplant superbug infection
A bacteriophage engineered with CRISPR successfully treated a patient with an antibiotic-resistant E. coli infection after transplant.
Chosunbiz · +3 outlets
mRNA immunotherapy eliminates pancreatic tumors in mice, UMass Chan study finds
A preclinical mRNA-based treatment cleared pancreatic tumors in mouse models, offering a new avenue against a notoriously hard-to-treat cancer.
UMass Chan Medical School · +4 outlets
Skylark Bio doses first child with GJB2 gene therapy for deafness
The first patient has been treated in a trial of an investigational gene therapy for a common genetic cause of hearing loss.
Tech Times · +3 outlets
Legend Biotech reports Q2 profitability as CARVYKTI sales surge 50%
The CAR-T therapy maker reached profitability in the second quarter driven by strong sales growth of its multiple myeloma drug.
sekbernews.id · +6 outlets
Boulevard Bio launches with $65M and trio of immunology antibodies targeting autoimmune disease
Co-founded by pioneer Georg Schett, the Deerfield-backed startup aims to develop multifaceted antibodies for several immune diseases.
BioPharma Dive · +2 outlets
Young adult vaping and cannabis use hit record highs in 2025, survey finds
A new survey reports that use of vapes and cannabis among young adults reached all-time highs last year.
STAT · +14 outlets
EIT Pharma's lonafarnib NDA accepted by FDA for chronic hepatitis D
The FDA has accepted the New Drug Application for lonafarnib, a potential treatment for chronic hepatitis delta virus.
contagionlive.com · +3 outlets